Sarah A. Polonius-Teichmann, a director of 10X Genomics, Inc., filed a Form 144 notice on November 20, 2026, disclosing a proposed sale of 4,000 shares of common stock on NASDAQ.
Key Highlights
- Seller: Sarah A. Polonius-Teichmann, identified in the filing as a Director of 10X Genomics, Inc.
- Shares proposed for sale: 4,000 shares of common stock, with an aggregate market value of $223,080.00.
- Source of shares: The shares were acquired on February 21, 2026, as restricted stock from the issuer.
- Approximate sale date: November 20, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of August 21, 2026.
- Shares outstanding: 10X Genomics reported 121,455,317 shares of common stock outstanding at the time of the filing.
- Prior sales: The filing reports nothing to disclose for securities sold during the past three months.
Polonius-Teichmann Discloses Proposed Common Stock Sale Under Rule 144
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Sarah A. Polonius-Teichmann, a director of 10X Genomics, Inc. (NASDAQ:TXG), is proposing to sell 4,000 shares of the company's common stock. The filing lists an aggregate market value of $223,080.00 for the shares to be sold. The proposed transaction is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
The filing discloses that the 4,000 shares were acquired on February 21, 2026, through a restricted stock grant from the issuer, with payment listed as "Not Applicable." The notice was filed on November 20, 2026, and lists the same date as the approximate date of sale. The filing also indicates that Polonius-Teichmann adopted a written trading plan pursuant to Rule 10b5-1 under the Exchange Act on August 21, 2026. By signing the notice, the filer represents, as of the plan adoption date, that she did not know of any material adverse information regarding the current and prospective operations of 10X Genomics that had not been publicly disclosed.
The filing states there are no securities sold during the past three months to report for the account of the selling person. At the time of filing, 10X Genomics reported 121,455,317 shares of common stock outstanding. The company's issuer address is listed as 6230 Stoneridge Mall Road, Pleasanton, California 94588.
What Was Disclosed
A Form 144 notice was filed on November 20, 2026, by 10X Genomics director Sarah A. Polonius-Teichmann, covering a proposed sale of 4,000 restricted stock shares with an aggregate market value of $223,080.00, under a Rule 10b5-1 plan adopted August 21, 2026.



Please wait processing your request...